CytRx Corporation (CYTR) News

CytRx Corporation (CYTR): $0.09

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Add CYTR to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#179 of 493

in industry

Filter CYTR News Items

CYTR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CYTR News Highlights

  • For CYTR, its 30 day story count is now at 2.
  • Over the past 12 days, the trend for CYTR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest CYTR News From Around the Web

Below are the latest news stories about CYTRX CORP that investors may wish to consider to help them evaluate CYTR as an investment opportunity.

LadRx Corporation Announces OTCQB Ticker Change to LADX

LOS ANGELES, October 05, 2022--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday, October 6, 2022.

Yahoo | October 5, 2022

CytRx Corporation Relaunches as LadRx Corporation

LOS ANGELES, September 23, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces that it is relaunching as LadRx Corporation.

Yahoo | September 23, 2022

European Patent Office Awards CytRx Key Patent

LOS ANGELES, September 07, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has been awarded a key patent by the European Patent Office, and that the period for parties to oppose the patent has lapsed without opposition.

Yahoo | September 7, 2022

CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors

LOS ANGELES, August 09, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, welcomes Mr. Cary J. Claiborne to the CytRx Board of Directors (the "Board").

Yahoo | August 9, 2022

CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock

LOS ANGELES, May 19, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 pm Eastern Time on May 20, 2022. The outstanding shares of

Yahoo | May 19, 2022

CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.

LOS ANGELES, May 17, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic purchase of arimoclomol by KemPharm, Inc. ("KemPharm").

Yahoo | May 17, 2022

CytRx Partners with Oncology Development Expert to Advance LADR Platform

LOS ANGELES, April 20, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has partnered with oncology development expert Gilad Gordon, MD to assist the Company in developing its next-generation LADR drugs toward first-in-human clinical trials.

Yahoo | April 20, 2022

CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress

LOS ANGELES, March 21, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below letter to stockholders.

Yahoo | March 21, 2022

CytRx Announces Integration of Wholly Owned Subsidiary Centurion BioPharma and Corporate Governance Updates

LOS ANGELES, March 09, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that the Company is absorbing its wholly-owned subsidiary Centurion BioPharma Corporation ("Centurion"). All of Centurion’s assets will be absorbed by the Company via a merger agreement. Centurion’s assets consist of the high-potential LADR platform for the concentration and localized deliver

Yahoo | March 9, 2022

CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C

LOS ANGELES, February 24, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on Orphazyme A/S's (NASDAQ: ORPH) ("Orphazyme") announced update on the ongoing review of the Marketing Authorisation Application for its investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C ("NPC") by the Committee for Medic

Yahoo | February 24, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!